6u3o › Citations

T cell receptor cross-reactivity between gliadin and bacterial peptides in celiac disease.

Petersen J, Ciacchi L, Tran MT, Loh KL, Kooy-Winkelaar Y, Croft NP, Hardy MY, Chen Z, McCluskey J, Anderson RP, Purcell AW, Tye-Din JA, Koning F, Reid HH, Rossjohn J
Nat Struct Mol Biol 27 49-61 (2020)
Related entries: 6u3m, 6u3n

Cited: 45 times
EuropePMC logo PMID: 31873306

Abstract

The human leukocyte antigen (HLA) locus is strongly associated with T cell-mediated autoimmune disorders. HLA-DQ2.5-mediated celiac disease (CeD) is triggered by the ingestion of gluten, although the relative roles of genetic and environmental risk factors in CeD is unclear. Here we identify microbially derived mimics of gliadin epitopes and a parental bacterial protein that is naturally processed by antigen-presenting cells and activated gliadin reactive HLA-DQ2.5-restricted T cells derived from CeD patients. Crystal structures of T cell receptors in complex with HLA-DQ2.5 bound to two distinct bacterial peptides demonstrate that molecular mimicry underpins cross-reactivity toward the gliadin epitopes. Accordingly, gliadin reactive T cells involved in CeD pathogenesis cross-react with ubiquitous bacterial peptides, thereby suggesting microbial exposure as a potential environmental factor in CeD.

Reviews - 6u3o mentioned but not cited (1)

  1. The Many Faces of CD4+ T Cells: Immunological and Structural Characteristics. Chatzileontiadou DSM, Sloane H, Nguyen AT, Gras S, Grant EJ. Int J Mol Sci 22 E73 (2020)

Articles - 6u3o mentioned but not cited (1)



Reviews citing this publication (25)

  1. The microbiome and human cancer. Sepich-Poore GD, Zitvogel L, Straussman R, Hasty J, Wargo JA, Knight R. Science 371 eabc4552 (2021)
  2. Interaction between drugs and the gut microbiome. Weersma RK, Zhernakova A, Fu J. Gut 69 1510-1519 (2020)
  3. Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities. Vesterhus M, Karlsen TH. J Gastroenterol 55 588-614 (2020)
  4. Coeliac Disease Pathogenesis: The Uncertainties of a Well-Known Immune Mediated Disorder. Dunne MR, Byrne G, Chirdo FG, Feighery C. Front Immunol 11 1374 (2020)
  5. Antibiotics in the pathogenesis of diabetes and inflammatory diseases of the gastrointestinal tract. Fenneman AC, Weidner M, Chen LA, Nieuwdorp M, Blaser MJ. Nat Rev Gastroenterol Hepatol 20 81-100 (2023)
  6. Immunopathogenesis and environmental triggers in coeliac disease. Levescot A, Malamut G, Cerf-Bensussan N. Gut gutjnl-2021-326257 (2022)
  7. Interplay Between Gluten, HLA, Innate and Adaptive Immunity Orchestrates the Development of Coeliac Disease. Voisine J, Abadie V. Front Immunol 12 674313 (2021)
  8. Type 2 Transglutaminase in Coeliac Disease: A Key Player in Pathogenesis, Diagnosis and Therapy. Paolella G, Sposito S, Romanelli AM, Caputo I. Int J Mol Sci 23 7513 (2022)
  9. Gut microbiota in Celiac Disease: microbes, metabolites, pathways and therapeutics. Olshan KL, Leonard MM, Serena G, Zomorrodi AR, Fasano A. Expert Rev Clin Immunol 16 1075-1092 (2020)
  10. A Cumulative Effect of Food and Viruses to Trigger Celiac Disease (CD): A Commentary on the Recent Literature. Barone MV, Auricchio S. Int J Mol Sci 22 2027 (2021)
  11. Molecular Biomarkers for Celiac Disease: Past, Present and Future. Ramírez-Sánchez AD, Tan IL, Gonera-de Jong BC, Visschedijk MC, Jonkers I, Withoff S. Int J Mol Sci 21 E8528 (2020)
  12. IgE-Mediated Peanut Allergy: Current and Novel Predictive Biomarkers for Clinical Phenotypes Using Multi-Omics Approaches. Czolk R, Klueber J, Sørensen M, Wilmes P, Codreanu-Morel F, Skov PS, Hilger C, Bindslev-Jensen C, Ollert M, Kuehn A. Front Immunol 11 594350 (2020)
  13. Celiac disease: mechanisms and emerging therapeutics. Besser HA, Khosla C. Trends Pharmacol Sci 44 949-962 (2023)
  14. Why are western diet and western lifestyle pro-inflammatory risk factors of celiac disease? Skoracka K, Hryhorowicz S, Rychter AM, Ratajczak AE, Szymczak-Tomczak A, Zawada A, Słomski R, Dobrowolska A, Krela-Kaźmierczak I. Front Nutr 9 1054089 (2022)
  15. Celiac Disease and Possible Dietary Interventions: From Enzymes and Probiotics to Postbiotics and Viruses. Wagh SK, Lammers KM, Padul MV, Rodriguez-Herrera A, Dodero VI. Int J Mol Sci 23 11748 (2022)
  16. The Role of Intestinal Microbiota in Celiac Disease and Further Therapeutic Perspectives. Belei O, Jugănaru I, Basaca DG, Munteanu AI, Mărginean O. Life (Basel) 13 2039 (2023)
  17. The double-edged sword of gut bacteria in celiac disease and implications for therapeutic potential. Galipeau HJ, Verdu EF. Mucosal Immunol 15 235-243 (2022)
  18. A Comprehensive Review of the Neurological Manifestations of Celiac Disease and Its Treatment. Gala D, Scharf S, Kudlak M, Green C, Khowaja F, Shah M, Kumar V, Ullal G. Diseases 10 111 (2022)
  19. Beyond the Gut: A Systematic Review of Oral Manifestations in Celiac Disease. Lucchese A, Di Stasio D, De Stefano S, Nardone M, Carinci F. J Clin Med 12 3874 (2023)
  20. The Contribution of the Intestinal Microbiota to the Celiac Disease Pathogenesis along with the Effectiveness of Probiotic Therapy. Zolnikova O, Dzhakhaya N, Bueverova E, Sedova A, Kurbatova A, Kryuchkova K, Butkova T, Izotov A, Kulikova L, Yurku K, Chekulaev P, Zaborova V. Microorganisms 11 2848 (2023)
  21. The Multiomics Analyses of Fecal Matrix and Its Significance to Coeliac Disease Gut Profiling. Gangadoo S, Rajapaksha Pathirannahalage P, Cheeseman S, Dang YTH, Elbourne A, Cozzolino D, Latham K, Truong VK, Chapman J. Int J Mol Sci 22 1965 (2021)
  22. The good and the bad of T cell cross-reactivity: challenges and opportunities for novel therapeutics in autoimmunity and cancer. Gouttefangeas C, Klein R, Maia A. Front Immunol 14 1212546 (2023)
  23. Emerging Pharmaceutical Therapies to Address the Inadequacy of a Gluten-Free Diet for Celiac Disease. Crepaldi M, Palo M, Maniero D, Bertin L, Savarino EV, Anderson RP, Zingone F. Pharmaceuticals (Basel) 17 4 (2023)
  24. Influence of Microbiota on Tumor Immunotherapy. Yu X, Li W, Li Z, Wu Q, Sun S. Int J Biol Sci 20 2264-2294 (2024)
  25. Review article: Becoming and being coeliac-special considerations for childhood, adolescence and beyond. Chang D, O'Shea D, Therrien A, Silvester JA. Aliment Pharmacol Ther 56 Suppl 1 S73-S85 (2022)

Articles citing this publication (18)



Quick links